Valuable Targets

Histamine receptor antagonists: What They Are and How to Stay Informed About Recent Advances

2 January 2024
4 min read

Histamine receptors are proteins found in the human body that play a crucial role in various physiological processes. They are primarily involved in mediating the effects of histamine, a chemical released by cells in response to injury or allergic reactions. Histamine receptors are classified into four types: H1, H2, H3, and H4. H1 receptors are present in smooth muscles, blood vessels, and the central nervous system, and their activation can lead to allergic reactions and inflammation. H2 receptors are mainly found in the stomach lining and are involved in regulating gastric acid secretion. H3 receptors are primarily located in the brain and modulate neurotransmitter release. H4 receptors are found in immune cells and are implicated in immune responses. Understanding the role of histamine receptors is crucial for developing drugs that target these receptors to treat various conditions.

Histamine receptor antagonists, also known as antihistamines, are a class of medications that block the action of histamine at its receptors. They are used to relieve allergic reactions and other conditions mediated by histamine. There are two main types of histamine receptors: H1 and H2.

H1 antagonists, also called H1 blockers, block the action of histamine at the H1 receptor, helping to relieve allergic reactions. They are used in the treatment of histamine-mediated allergic conditions.

H2 antagonists, sometimes referred to as H2RAs and also called H2 blockers, block the action of histamine at the histamine H2 receptors of the parietal cells in the stomach. This decreases the production of stomach acid. H2 antagonists can be used in the treatment of dyspepsia, peptic ulcers, and gastroesophageal reflux disease.

The analysis of the target Histamine receptor reveals a competitive landscape with multiple companies making progress in the development of drugs. GSK Plc and Sanofi are leading in terms of the highest stage of development, with several approved drugs. The indications for these drugs cover a wide range of conditions, including common cold, allergies, hypersensitivity, and more. Small molecule drugs are the most rapidly progressing drug type, indicating intense competition in the market. China, the United States, and Japan are the countries/locations developing fastest under this target, with China leading in terms of the number of approved drugs. The future development of the target Histamine receptor is promising, with ongoing research and development efforts by various companies and countries.

How do they work?

Histamine receptor agonists are a type of drugs that bind to and activate histamine receptors in the body. Histamine receptors are proteins found on the surface of cells, particularly in the respiratory tract, gastrointestinal tract, and central nervous system. When histamine receptor agonists bind to these receptors, they mimic the action of histamine, a chemical messenger released by the immune system in response to allergens or injury.

From a biomedical perspective, histamine receptor agonists are commonly used in the treatment of allergic conditions such as allergic rhinitis (hay fever), urticaria (hives), and allergic conjunctivitis. By activating histamine receptors, these drugs help to relieve symptoms associated with allergies, such as nasal congestion, itching, sneezing, and watery eyes.

Histamine receptor agonists can be further classified based on their selectivity for different types of histamine receptors, namely H1, H2, H3, and H4 receptors. Each subtype of histamine receptor has different functions and is found in different tissues. For example, H1 receptors are mainly present in the respiratory tract and are involved in allergic reactions, while H2 receptors are found in the stomach and play a role in regulating gastric acid secretion.

Overall, histamine receptor agonists are important therapeutic agents in the field of biomedicine, as they help to modulate the effects of histamine in various physiological processes and provide relief from allergic symptoms.

List of Histamine receptor Antagonists

The currently marketed Histamine receptor antagonists include:

For more information, please click on the image below.

图形用户界面, 应用程序

描述已自动生成

What are Histamine receptor antagonists used for?

Histamine receptor antagonists are commonly used in the treatment of allergic conditions such as allergic rhinitis (hay fever), urticaria (hives), and allergic conjunctivitis.  For more information, please click on the image below to log in and search.

应用程序

中度可信度描述已自动生成

How to obtain the latest development progress of Histamine receptor antagonists?

In the Synapse database, you can keep abreast of the latest research and development advances of Histamine receptor antagonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 表格

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

CD20-Targeted Antibody, Rituxan, Sanctioned for Prevention and Therapy of Organ Rejection Due to Antibodies
Latest Hotspot
3 min read
CD20-Targeted Antibody, Rituxan, Sanctioned for Prevention and Therapy of Organ Rejection Due to Antibodies
2 January 2024
Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. have announced obtaining approval from Japan's Ministry of Health, Labour and Welfare to commercially distribute Rituxan®.
Read →
What are the effects of ubiquitination on protein degradation?
"What" Series
2 min read
What are the effects of ubiquitination on protein degradation?
2 January 2024
Ubiquitination is a process that involves adding a protein called ubiquitin to a substrate protein.
Read →
Demystifying H2 receptor antagonists: A Comprehensive Guide and How to Keep Up with the Latest Developments
Demystifying H2 receptor antagonists: A Comprehensive Guide and How to Keep Up with the Latest Developments
2 January 2024
H2 receptor antagonists are drugs that inhibit histamine action in the stomach, reducing acid production.
Read →
Mineralys Therapeutics Announces First Patient Dosed in Start-HTN, Its Second Key Trial of Lorundrostat for Hypertension Control
Latest Hotspot
3 min read
Mineralys Therapeutics Announces First Patient Dosed in Start-HTN, Its Second Key Trial of Lorundrostat for Hypertension Control
2 January 2024
Mineralys Therapeutics Reports Initial Participant Receives Dose in Start-HTN, Their Second Major Study of Lorundrostat Aimed at Hypertension Management.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.